SmartWand: Validating a Novel Device for Remote Pelvic Floor Physical Therapy.

High-tone pelvic floor dysfunction (HTPFD) affects a substantial proportion of women with chronic pelvic pain and is characterized by hypertonic musculature, myofascial tenderness, dyspareunia, and urinary and defecatory symptoms. Although pelvic floor physical therapy (PFPT) is the first-line treatment, access is severely limited: only 2.47% of U.S. zip codes have even one trained pelvic floor physical therapist, and completion rates at some referral centers are as low as 20%. Existing telehealth and home biofeedback tools support muscle-strengthening exercises but cannot guide patients to therapist-defined myofascial trigger points or objectively verify that therapeutic depth, rotational orientation, and force are reproduced during home-based treatment-capabilities essential for HTPFD management. We developed the SmartWand, a Bluetooth-enabled intravaginal device that quantifies insertion depth (cm), rotational orientation (degrees), and applied force (kg/cm2) and pairs with a smartphone application to deliver real-time, multimodal guidance. Using a two-phase workflow, a pelvic floor physical therapist first programs patient-specific trigger-point coordinates during an in-clinic session; the patient then independently reproduces those coordinates at home with on-screen directional feedback, auditory confirmation, and haptic cues. In this prospective validation study, 20 adult women-10 with HTPFD and 10 healthy controls-underwent therapist-guided pelvic floor mapping at eight anatomical sites followed by blinded, independent coordinate reproduction. Inter-rater reliability between therapist-programmed and participant-reproduced measurements was assessed using intraclass correlation coefficients (ICC) from two-way mixed-effects models with subject-specific random intercepts to account for repeated within-subject measures. The SmartWand demonstrated excellent agreement for insertion depth (ICC 0.98; 95% CI 0.971-0.986) and rotational orientation (ICC 0.999; 95% CI 0.998-0.999), and good agreement for applied force (ICC 0.877; 95% CI 0.82-0.916). All ICC values surpassed the prespecified success threshold of 0.65. Critically, reliability was consistent across both participant groups, indicating that the hypertonic musculature and myofascial tenderness characteristic of HTPFD did not impair measurement reproducibility. These findings establish proof-of-concept that patients can independently perform technique-specific internal myofascial release-previously considered feasible only under direct therapist supervision-with objective, quantitative verification of accuracy. The SmartWand system represents a meaningful technological advance over existing home biofeedback platforms by enabling therapist-programmed spatial targeting and calibrated force delivery at patient-specific trigger points. By digitizing treatment parameters and generating objective adherence data, this technology has the potential to expand guideline-concordant PFPT to the millions of women with HTPFD who currently cannot access or complete in-person care, and to support standardized dosing and longitudinal monitoring in future hybrid telehealth care models. Randomized controlled trials comparing SmartWand-augmented hybrid PFPT to standard in-person therapy are warranted to establish clinical efficacy.